J.Safra Asset Management Corp Buys 19,685 Shares of VanEck Pharmaceutical ETF $PPH

J.Safra Asset Management Corp raised its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 6.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 305,472 shares of the company’s stock after acquiring an additional 19,685 shares during the period. VanEck Pharmaceutical ETF makes up 1.7% of J.Safra Asset Management Corp’s holdings, making the stock its 16th largest position. J.Safra Asset Management Corp owned 2.77% of VanEck Pharmaceutical ETF worth $31,516,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PPH. Citigroup Inc. grew its stake in VanEck Pharmaceutical ETF by 987.8% in the third quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock valued at $64,896,000 after acquiring an additional 652,175 shares during the period. BNP Paribas Financial Markets boosted its stake in VanEck Pharmaceutical ETF by 176.2% in the 4th quarter. BNP Paribas Financial Markets now owns 300,000 shares of the company’s stock worth $30,951,000 after purchasing an additional 191,371 shares during the period. JPMorgan Chase & Co. boosted its stake in VanEck Pharmaceutical ETF by 0.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 256,985 shares of the company’s stock worth $23,221,000 after purchasing an additional 1,148 shares during the period. Revere Asset Management Inc acquired a new position in VanEck Pharmaceutical ETF in the 3rd quarter worth $15,628,000. Finally, Adamsbrown Wealth Consultants LLC boosted its stake in VanEck Pharmaceutical ETF by 4.5% in the 4th quarter. Adamsbrown Wealth Consultants LLC now owns 143,045 shares of the company’s stock worth $14,758,000 after purchasing an additional 6,146 shares during the period.

VanEck Pharmaceutical ETF Trading Down 0.6%

Shares of NASDAQ PPH opened at $105.29 on Thursday. The firm has a market cap of $999.20 million, a PE ratio of 20.21 and a beta of 0.47. VanEck Pharmaceutical ETF has a 1-year low of $81.74 and a 1-year high of $112.58. The company has a fifty day moving average price of $102.91 and a 200 day moving average price of $104.29.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Wednesday, April 1st were given a $0.8441 dividend. This is a boost from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31. This represents a $3.38 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend was Wednesday, April 1st.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.